
Functional heartburn is a common disorder and appears to be composed of several distinct subgroups. Identifying the different subgroups based on clinical history only is not achievable at present. The mechanisms responsible for pain, clinical characteristics, and the optimal therapeutic approach remain poorly understood. Response to potent antireflux treatment is relatively limited. Current and future treatment strategies for functional heartburn patients who have failed standard dose proton pump inhibitors (PPIs) include increased PPI dose in some, as well as addition of pain modulators in others.
Male, Sensation, Proton Pump Inhibitors, Anti-Ulcer Agents, Esophagus, Heartburn, Gastroesophageal Reflux, Humans, Female, Serotonin Antagonists, Selective Serotonin Reuptake Inhibitors
Male, Sensation, Proton Pump Inhibitors, Anti-Ulcer Agents, Esophagus, Heartburn, Gastroesophageal Reflux, Humans, Female, Serotonin Antagonists, Selective Serotonin Reuptake Inhibitors
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 203 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
